Adagene
ADAG
15 hedge funds and large institutions have $29.7M invested in Adagene in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0.03% more ownership
Funds ownership: 15.39% → 15.43% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 16 → 15 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
56% less capital invested
Capital invested by funds: $67.3M → $29.7M (-$37.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVI
Strategic Vision Investment
Hong Kong
|
+$3.91M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$64.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$23.4K |
| 4 |
Morgan Stanley
New York
|
+$4.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.12M |
| 2 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$1M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$648K |
| 4 |
EFM
E Fund Management
Guangzhou,
China
|
-$219K |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$159K |
ADAG Hedge Fund Activity: Q1 2022 in Review
15 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Adagene (ADAG) for Q1 2022, worth a combined $29.7M — down 56% from $67.3M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ADAG and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.
The largest buyer was Strategic Vision Investment, adding an estimated $3.91M. The largest seller was OrbiMed, exiting entirely with an estimated $2.12M sold.
- 15 institutional investors held Adagene (ADAG) as of Q1 2022, down from 16 in Q4 2021.
- Funds reported $29.7M of Adagene stock for Q1 2022, down 56% quarter-over-quarter.
- 1 fund opened new Adagene positions in Q1 2022 and 2 closed out, a net change of -1 holder.
- The largest Adagene buyer in Q1 2022 was Strategic Vision Investment, an estimated $3.91M added.
- The largest Adagene seller in Q1 2022 was OrbiMed, an estimated $2.12M sold.
Based on aggregated 13F filings for Q1 2022.